Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor

Arthritis and Rheumatism

Volumn 41, Issue 1, 1998, Pages 139-149

  Su, Xiao ^a   Zhou, Tong ^a   Yang, Pingar ^a   Edwards III, Carl K ^b   Mountz, John D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE LUNG DISEASE; COMPETITIVE INHIBITION; CONTROLLED STUDY; FEMALE; IMMUNOTHERAPY; INFLAMMATORY DISEASE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; MOUSE MUTANT; NEWBORN; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; SKIN INFLAMMATION;

ALOPECIA; ANIMALS; ANTIGENS, CD; APOPTOSIS; ARTHRITIS; AUTOANTIBODIES; BINDING, COMPETITIVE; CARRIER PROTEINS; DIMERIZATION; LONGEVITY; MICE; MICE, INBRED C3H; MICE, MUTANT STRAINS; MUTATION; PNEUMONIA; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031982531     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.0.CO;2-T     Document Type: Article

References (71)

1. Green MC, Shultz LD. Motheaten, an immunodeficient mutant of the mouse. I. Genetics and pathology. J Hered 1975;66:250-8.
2. Shultz LD. Pleiotropic effects of deleterious alleles at the "motheaten" locus. Curr Top Microbiol Immunol 1988;137:216-22.
3. Shultz LD. Hematopoiesis and models of immunodeficiency. Semin Immunol 1991;3:397-408.
4. Shultz LD, Coman DR, Bailey CL, Beamer WG, Sidman CL. "Viable motheaten," a new allele at the motheaten locus. I. Pathology. Am J Pathol 1984;116:179-92.
5. + B cells in viable motheaten and normal mice. Science 1986;232:1423-5.
6. McCoy KL, Engel D, Clagett J. Accelerated rate of mononuclear phagocyte production in vitro by splenocytes from autoimmune motheaten mice. Am J Pathol 1983;112:18-26.
7. McCoy KL, Nielson K, Clagett J. Spontaneous production of colony-stimulating activity by splenic Mac-1 antigen-positive cells from autoimmune motheaten mice. J Immunol 1984;132:272-6.
8. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993;73:1445-54.
9. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the hematopoietic cell phosphatase gene. Nat Genet 1993;4:124-9.
10. Yi TL, Cleveland JI, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol 1992;12:836-46.
11. Shen SH, Bastien L, Posner BI, Chretien P. A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature 1991;352:736-9.
12. Zhao Z, Bouchard P, Diltz CD, Shen SH, Fischer EH. Purification and characterization of a protein tyrosine phosphatase containing SH2 domains. J Biol Chem 1993;268:2816-20.
13. Matthews RJ, Bowne DB, Flores E, Thomas ML. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol 1992;12:2396-405.
14. Plutzky J, Neel BG, Rosenberg RD. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A 1992;89:1123-7.
15. Plutzky J, Neel BG, Rosenberg RD, Eddy RL, Byers MG, Jani-Sait S, et al. Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). Genomics 1992;13:869-72.
16. Yi T, Mui AL, Krystal G, Ihle JN. Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol Cell Biol 1993;3:7577-86.
17. Yi T, Ihle JN. Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. Mol Cell Biol 1993;13:3350-8.
18. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
19. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
20. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
21. Brunner T, Mogil RJ, LuFace D, Yoo NJ, Mahboubi A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-4.
22. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
23. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
24. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoprolifcrative disease. Annu Rev Immunol 1991;9:243-69.
25. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoprolifcrative syndrome. Cell 1995;81:935-46.
26. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
27. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
28. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335:1643-9.
29. Su X, Zhou T, Wang Z, Yang P, Jope RS, Mountz JD. Defective expression of hematopoietic cell protein tyrosine phosphatase in lymphoid cells blocks Fas-mediated apoptosis. Immunity 1995;2:353-62.
30. Su X, Zhou T, Yang P, Wang Z, Mountz JD. HCP-deficient motheaten mice exhibit T cell apoptosis defect. J Immunol 1996;156:4198-208.
31. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-7.
32. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature 1995;377:348-51.
33. Zhou T, Edwards CK III, Yang P, Zheng W, Bluethmann H, Mountz JD. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996;156:2661-5.
34. Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995;40:365-94.
35. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
36. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, et al. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994;180:995-1004.
37. Guerder S, Picarella DE, Linsley PS, Flavell RA. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A 1994;91:5138-42.
38. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol 1995;42:158-65.
39. Feldmann M, Brennan FM, Williams RO, Cope AP, Gibbons DL, Katsikis PD, et al. Evaluation of the role cytokines in autoimmune disease: the importance of TNF α in rheumatoid arthritis. Prog Growth Factor Res 1992;4:247-55.
40. Gray PW, Barrett K, Chantry D, Turner M, Feldmann M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A 1990;87:7380-4.
41. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991;88:10535-9.
42. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
43. Englemann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990;265:14497-504.
44. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
45. Katre NV. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol 1990;144:209-13.
46. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
47. Klinkert WEF, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. TNF-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997;72:163-8.
48. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analysis published in cancer journals. Br J Cancer 1995;72:511-8.
49. + T cells in MRL-lpr/lpr mice: clues from a T cell receptor β transgenic mouse. J Immunol 1993;150:3651-67.
50. Zhou T, Bluethmann H, Zhang J, Edwards CK III, Mountz JD. Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice. J Exp Med 1992;176:1063-72.
51. Davidson WF, Morse HC III, Sharrow SO, Chused TM. Phenotypic and functional effects of motheaten gene on murine B and T lymphocytes. J Immunol 1979;122:884-91.
52. Sidman CL, Shultz LD, Unanue ER. The mouse mutant "motheaten." II. Functional studies of the immune system. J Immunol 1978;121:2399-404.
53. Lutzner MA, Hansen CT. Motheaten: an immunodeficient mouse with markedly less ability to survive than the nude mouse in a germfree environment. J Immunol 1976;116:1496-7.
54. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
55. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with a tumor necrosis factor receptor-Fc fusion protein. N Engl J Med 1996;334:1697-702.
56. Evans RJ, McCabe JG, Bendele AM, Kieft GL, McAbee TJ, Edwards CK III. Efficacy of tumor necrosis factor binding protein in streptococcal cell wall-induced reaction model of arthritis (abstract). Arthritis Rheum 39 Suppl 9:S284, 1996
57. Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997;40:397-409.
58. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995;84:433-9.
59. Eliaz R, Wallach D, Kost J. Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor. Cytokine 1996;8:482-7.
60. Moreland LW, Margolies GR, Heck LW, Saway PA, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
61. Gamble JR, Harrlan JR, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A 1985;82:8667-71.
62. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, et al. Monoclonal anti-TNF-α antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995;144:195-223.
63. Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumor necrosis factor-α (TNF-α) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995;101:207-12.
64. Bras A, Aguas AP. Mycobacteria-induced autoantibody production is associated with susceptibility to infection but not with host propensity to develop autoimmune disease. Clin Exp Immunol 1995;100:75-80.
65. Nose M, Nishimura M, Ito MR, Toh J, Shibata T, Sugisaki T. Arteritis in a novel congenic strain of mice derived from MRL/lpr lupus mice: genetic dissociation from glomerulonephritis and limited autoantibody production. Am J Pathol 1995;149:1763-9.
66. Pani G, Kozlowski M, Cambier JC, Mills GB, Siminovitch KA. Identification of the tyrosine phosphatase PTPIC as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling. J Exp Med 1995;181:2077-84.
67. Cyster JG, Goodnow CC. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 1995;2:13-24.
68. Lorenz U, Ravichandran KS, Burakoff SJ, Neel BG. Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness. Proc Natl Acad Sci U S A 1996;93:9624-9.
69. Lorenz U, Ravichandran KS, Pei D, Walsh CT, Burakoff SJ, Neel BG. Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase SH-PTP1 in murinc T cells. Mol Cell Biol 1994;14:1824-34.
70. Delesque N, Buscail L, Esteve JP, Rauly I, Zeggari M, Saint-Laurent N, et al. A tyrosine phosphatase is associated with the somatostatin receptor. Ciba Found Symp 1995;190:187-96.
71. Kharbanda S, Bharti A, Pei D, Wang J, Pandey P, Ren R, et al. The stress response to ionizing radiation involves c-Abl-dependent phosphorylation of SHPTP1. Proc Natl Acad Sci U S A 1996;93:6898-901.